全球脑膜炎双球菌疫苗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

全球脑膜炎双球菌疫苗市场需求预计将从 2023 年的 55.7 亿美元达到近 102.8 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 7.05%。

脑膜炎双球菌疫苗有助于预防脑膜炎双球菌疾病。脑膜炎球菌疾病是由脑膜炎奈瑟菌引起的。疫苗含有抗原物质，可以增强人体的免疫系统并使其产生抗体，然后这些抗体透过攻击和杀死细菌来保护身体。疫苗透过注射到肌肉或皮下注射。脑膜炎双球菌疫苗有三种类型：多醣体疫苗、结合疫苗和蛋白质疫苗。

市场动态

流行性脑膜炎发病率的不断上升正在推动市场的成长。脑膜炎球菌疾病可能是致命的，全世界所有国家都观察到这种疾病，但这种疾病的负担最重的是撒哈拉以南非洲地区，从西部的塞内加尔到东部的埃塞俄比亚。的浪潮增长归因于新型冠状病毒肺炎 (COVID-19)，这是一种新兴的、快速发展的情况。进行各种临床试验以确定结果。多种药物和疫苗被确定为根除 COVID-19 的候选药物和疫苗。 ChAdOx1 nCoV-19 脑膜炎双球菌疫苗就是其中之一。这种疫苗的作用是启动免疫系统识别和攻击冠状病毒，刺激 T 细胞反应，并且在动物和早期人体测试中似乎是安全的，这给冠状病毒版本和市场成长带来了信心。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球脑膜炎双球菌疫苗市场的各个细分市场进行了包容性评估。脑膜炎球菌疫苗产业的成长和趋势为本研究提供了整体方法。

市场区隔

脑膜炎球菌疫苗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按类型

• 二价
• 四价
• 其他的

按品牌

• 梅纳克特拉
• 门维奥
• 尼门里克斯
• 特鲁门巴
• 贝克塞罗
• 其他的

按年龄段

• 婴儿（0 至 2 岁）
• 儿童及成人（2岁以上）

依血清型分类

• A血清型
• B血清型
• C血清型
• 血清型 W-135
• Y血清型

按销售管道

• 私人的
• 民众

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲脑膜炎球菌疫苗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。脑膜炎球菌疫苗市场的主要参与者包括辉瑞公司、赛诺菲公司、印度血清研究所有限公司、葛兰素史克公司、默克公司、沃瓦克斯生物技术有限公司。整体视图其中包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：脑膜炎双球菌疫苗 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按类型分類的市场吸引力分析
  • 按品牌分類的市场吸引力分析
  • 按年龄组别分類的市场吸引力分析
  • 依血清型进行市场吸引力分析
  • 按销售管道分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球脑膜炎双球菌疫苗市场分析：按类型

• 按类型概述
• 历史和预测数据
• 按类型分析
• 二价
• 四价
• 其他的

第 6 章：全球脑膜炎双球菌疫苗市场分析：按品牌

• 按品牌概览
• 历史和预测数据
• 按品牌分析
• 梅纳克特拉
• 门维奥
• 尼门里克斯
• 特鲁门巴
• 贝克塞罗
• 其他的

第 7 章：全球脑膜炎双球菌疫苗市场分析：依年龄组别划分

• 依年龄组别概览
• 历史和预测数据
• 按年龄组分析
• 婴儿（0 至 2 岁）
• 儿童及成人（2岁以上）

第 8 章：全球脑膜炎双球菌疫苗市场分析：依血清型分类

• 按血清型概述
• 历史和预测数据
• 依血清型分析
• A血清型
• B血清型
• C血清型
• 血清型 W-135
• Y血清型

第 9 章：全球脑膜炎双球菌疫苗市场分析：按销售管道

• 销售通路概览
• 历史和预测数据
• 按销售管道分析
• 私人的
• 民众

第 10 章：全球脑膜炎双球菌疫苗市场分析：依地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区按国家销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲按国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 11 章：脑膜炎双球菌疫苗公司的竞争格局

• 脑膜炎双球菌疫苗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 12 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Pfizer Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Sanofi
• 公司概况
• 公司收入
• 产品
• 最新动态
• Serum Institute Of India Ltd.
• 公司概况
• 公司收入
• 产品
• 最新动态
• GSK Plc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Merck & Co. Inc.
• 公司概况
• 公司收入
• 产品
• 最新动态
• Walvax Biotechnology Co. Ltd
• 公司概况
• 公司收入
• 产品
• 最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

The global demand for Meningococcal Vaccine Market is presumed to reach the market size of nearly USD 10.28 Billion by 2032 from USD 5.57 Billion in 2023 with a CAGR of 7.05% under the study period 2024-2032.

Meningococcal vaccine helps prevent meningococcal disease. The meningococcal disease is caused by Neisseria meningitides bacteria. The vaccines contain antigens substances that boost the body's immune system and cause it to make antibodies, these antibodies then protect the body by attacking and killing the bacteria. The vaccine is given either by injection into a muscle or just under the skin. There are three types of meningococcal vaccines available: Polysaccharide vaccines, conjugate vaccines, and protein based vaccine.

MARKET DYNAMICS

Growing incidence of meningococcal meningitis is driving the growth of market. Meningococcal disease is potentially fatal, observed worldwide with reportable condition in all states, but the highest burden of the disease is in the sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east.Market is predicted to experience new waves in the growth owing to the COVID-19, an emerging an rapidly evolving situation.Scientist across the world are focused on discovering vaccine for coronavirus. Various clinical trials are executed to determine the results. Number of drugs and vaccine is identified as candidate to eradicate COVID-19. ChAdOx1 nCoV-19, vaccine against meningococcal disease is among the one. This vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response and has appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version and market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Meningococcal Vaccine. The growth and trends of Meningococcal Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Meningococcal Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Bivalent
• Quadrivalent
• Others

By Brand

• Menactra
• Menveo
• Nimenrix
• Trumenba
• Bexsero
• Others

By Age Group

• Infants (0 to 2 years)
• Children and Adults (2 years & above)

By Serotype

• Serotype A
• Serotype B
• Serotype C
• Serotype W-135
• Serotype Y

By Sales Channel

• Private
• Public

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Meningococcal Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Meningococcal Vaccine market include Pfizer Inc., Sanofi, Serum Institute Of India Ltd., GSK Plc., Merck & Co. Inc., Walvax Biotechnology Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MENINGOCOCCAL VACCINE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Brand
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By Serotype
  • 3.7.5 Market Attractiveness Analysis By Sales Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Type
• 5.4. Bivalent Historic and Forecast Sales By Regions
• 5.5. Quadrivalent Historic and Forecast Sales By Regions
• 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY BRAND

• 6.1. Overview By Brand
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Brand
• 6.4. Menactra Historic and Forecast Sales By Regions
• 6.5. Menveo Historic and Forecast Sales By Regions
• 6.6. Nimenrix Historic and Forecast Sales By Regions
• 6.7. Trumenba Historic and Forecast Sales By Regions
• 6.8. Bexsero Historic and Forecast Sales By Regions
• 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Age Group
• 7.4. Infants (0 to 2 years) Historic and Forecast Sales By Regions
• 7.5. Children and Adults (2 years & above) Historic and Forecast Sales By Regions

8. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SEROTYPE

• 8.1. Overview By Serotype
• 8.2. Historical and Forecast Data
• 8.3. Analysis By Serotype
• 8.4. Serotype A Historic and Forecast Sales By Regions
• 8.5. Serotype B Historic and Forecast Sales By Regions
• 8.6. Serotype C Historic and Forecast Sales By Regions
• 8.7. Serotype W-135 Historic and Forecast Sales By Regions
• 8.8. Serotype Y Historic and Forecast Sales By Regions

9. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SALES CHANNEL

• 9.1. Overview By Sales Channel
• 9.2. Historical and Forecast Data
• 9.3. Analysis By Sales Channel
• 9.4. Private Historic and Forecast Sales By Regions
• 9.5. Public Historic and Forecast Sales By Regions

10. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE MENINGOCOCCAL VACCINE COMPANIES

• 11.1. Meningococcal Vaccine Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF MENINGOCOCCAL VACCINE INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Pfizer Inc.
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Sanofi
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Serum Institute Of India Ltd.
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. GSK Plc.
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Merck & Co. Inc.
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Walvax Biotechnology Co. Ltd
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Type (USD MN)
• Bivalent Market Sales By Geography (USD MN)
• Quadrivalent Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Brand (USD MN)
• Menactra Market Sales By Geography (USD MN)
• Menveo Market Sales By Geography (USD MN)
• Nimenrix Market Sales By Geography (USD MN)
• Trumenba Market Sales By Geography (USD MN)
• Bexsero Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Age Group (USD MN)
• Infants (0 to 2 years) Market Sales By Geography (USD MN)
• Children and Adults (2 years & above) Market Sales By Geography (USD MN)
• Analysis By Serotype (USD MN)
• Serotype A Market Sales By Geography (USD MN)
• Serotype B Market Sales By Geography (USD MN)
• Serotype C Market Sales By Geography (USD MN)
• Serotype W-135 Market Sales By Geography (USD MN)
• Serotype Y Market Sales By Geography (USD MN)
• Analysis By Sales Channel (USD MN)
• Private Market Sales By Geography (USD MN)
• Public Market Sales By Geography (USD MN)
• Global Meningococcal Vaccine Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Meningococcal Vaccine Report
• Market Research Process
• Market Research Methodology
• Global Meningococcal Vaccine Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Type
• Market Attractiveness Analysis By Brand
• Market Attractiveness Analysis By Age Group
• Market Attractiveness Analysis By Serotype
• Market Attractiveness Analysis By Sales Channel
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Type (USD MN)
• Bivalent Market Sales By Geography (USD MN)
• Quadrivalent Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Brand (USD MN)
• Menactra Market Sales By Geography (USD MN)
• Menveo Market Sales By Geography (USD MN)
• Nimenrix Market Sales By Geography (USD MN)
• Trumenba Market Sales By Geography (USD MN)
• Bexsero Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Age Group (USD MN)
• Infants (0 to 2 years) Market Sales By Geography (USD MN)
• Children and Adults (2 years & above) Market Sales By Geography (USD MN)
• Global Market Analysis By Serotype (USD MN)
• Serotype A Market Sales By Geography (USD MN)
• Serotype B Market Sales By Geography (USD MN)
• Serotype C Market Sales By Geography (USD MN)
• Serotype W-135 Market Sales By Geography (USD MN)
• Serotype Y Market Sales By Geography (USD MN)
• Global Market Analysis By Sales Channel (USD MN)
• Private Market Sales By Geography (USD MN)
• Public Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.